Please login to the form below

Not currently logged in

Pfizer’s Vyndaqel is first EU therapy for ATTR cardiomyopathy

EU approval will help drug achieve blockbuster status

Pfizer HQ

Pfizer’s resurgent rare disease drug Vyndaqel has had its uses extended by the EMA, becoming the first drug in the EU for cardiomyopathy resulting from rare disease transthyretin-mediated amyloidosis (ATTR).

Vyndaqel (tafamidis meglumine) has been approved since 2011 for stage 1 polyneuropathy associated with ATTR, but the cardiomyopathy approval significantly extends the eligible patient population for the drug, already growing quickly following its approval for the latter indication in the US last May.

Sales of the once-daily, oral drug picked up dramatically after it was approved by the FDA, reaching $213m in the fourth quarter from $39m a year earlier, and the EU approval will help it achieve its long-anticipated blockbuster status.

In the ATTR polyneuropathy indication it has competition from Alnylam’s injectable drugs Onpattro (patisiran) and Ionis’ Tegsedi (inotersen), which were approved for that use in Europe in 2018.

Cardiomyopathy is the most serious of the symptoms seen in patients with hereditary or wild-type ATTR, a condition that means a type of amyloid protein known as transthyretin gets deposited in organs, stopping them from working correctly. In the heart, it causes stiffness in the muscle walls that impairs pumping and can lead to heart failure.

The latest approval is based on the results of the phase 3 ATTR-ACT study, showed that Vyndaqel reduced all-cause mortality over a 30-month period by 30% compared to placebo in patients with ATTR cardiomyopathy, reducing the death rate from around 43% to 29.5%.

Prior to Vyndaqel, treatment options for patients with ATTR cardiomyopathy were restricted to symptom management and – in rare cases – a heart transplant, according to Pfizer.

The lack of alternatives and mortality data has driven rapid take-up of the drug in the US, as well as diagnosis of the disease.

By end of 2019 more than 9,000 ATTR cardiomyopathy patients had been diagnosed in the US – raising the diagnosis rate from 1% pre-Vyndaqel launch to around 9%, according to Pfizer.

Meanwhile, more than 5,500 patients had been prescribed the $225,000 per year drug at that cut-off, and over 3,000 had already received it. The drug has also been approved for the cardiomyopathy indication in Japan, Brazil and Canada.

Article by
Phil Taylor

19th February 2020

From: Regulatory



COVID-19 Updates and Daily News

Featured jobs


Add my company

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Peter Howarth
Exploring the potential of eosinophils
GSK’s Peter Howarth talks about the emerging research that suggests there is a varied role for eosinophils...
white house
Eliminating pharmaceutical rebates, is this déjà vu?
By Andrew Parece and Matthew Majewski...
Patients are ready to embrace decentralised clinical trials, are you?
Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...